OBI Pharma Announces Phase 2 Studies Patient Enrollment for OBI-999 and OBI-3424

SOLID TUMOR PATIENTS WITH HIGH GLOBO H OR AKR1C3 EXPRESSION WILL BE ENROLLED. TAIPEI, Taiwan, January 24, 2022 — OBI Pharma, a Taiwan biopharma company (TPEx: 4174), today announced that the first patients have been enrolled in both of the Phase 2 studies of OBI-999, an antibody drug conjugate (ADC) cancer therapy targeting Globo H, […]

This article is password protected.

To view the content, please enter your password in the field below